Because ATR inhibitors have been shown to alter the tumor immune microenvironment by activating NK cells and increasing the number of tumor-infiltrating lymphocytes,33 a phase II trial was performed to study combination durvalumab (anti-PD-L1) and ceralasertib in patients with advanced GC in the second or later line (n = 31).36 Here, ATR is linked to neoplasm.